UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Cancer discovery, 2014-09, Vol.4 (9), p.1046-1061

2014

Volltextzugriff (PDF)

Temperature-Dependent Infrared Refractive Index of Polymers from a Calibrated Attenuated Total Reflection Infrared Measurement

Applied spectroscopy, 2022-10, Vol.76 (10), p.1254-1262

2022

Volltextzugriff (PDF)

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Cancer chemotherapy and pharmacology, 2016-04, Vol.77 (4), p.767-776

2016

Volltextzugriff (PDF)

ZD1839 (Iressa™): For More Than Just Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2002-08, Vol.7 (S4), p.16-24

Ranson, Malcolm

2002

Volltextzugriff (PDF)

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

Journal of clinical oncology, 2009-04, Vol.27 (10), p.1660-1666

2009

Volltextzugriff (PDF)

Multiplexed Assays for Detection of Mutations in PIK3CA

Clinical chemistry (Baltimore, Md.), 2008-04, Vol.54 (4), p.757-760

2008

Volltextzugriff (PDF)

Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer

Neoplasia (New York, N.Y.), 2011-04, Vol.13 (4), p.339-347

2011

Volltextzugriff (PDF)

Perspectives on Anti-HER Monoclonal Antibodies

Oncology, 2002-01, Vol.63 (Suppl 1), p.17-24

2002

Volltextzugriff (PDF)

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

Biomarker Insights, 2007-01, Vol.2, p.307-319

2007

Volltextzugriff (PDF)

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Theranostics, 2011-01, Vol.1 (1), p.290-301

2011

Volltextzugriff (PDF)

Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone

Clinical cancer research, 2005-04, Vol.11 (7), p.2695-2701

2005

Volltextzugriff (PDF)

Dual repair modulation reverses Temozolomide resistance in vitro

Molecular cancer therapeutics, 2004-02, Vol.3 (2), p.123-127

2004

Volltextzugriff (PDF)

Biomarkers of cell death applicable to early clinical trials

Experimental cell research, 2012-07, Vol.318 (11), p.1252-1259

2012

Volltextzugriff (PDF)

EGFR T790M mutation testing within the osimertinib AURA Phase I study

Lung cancer (Amsterdam, Netherlands), 2017-07, Vol.109, p.9-13

2017

Volltextzugriff (PDF)

Panitumumab: A Viewpoint by Malcolm Ranson

Drugs (New York, N.Y.), 2006-01, Vol.66 (15), p.2015-2016

Ranson, Malcolm

2006

Volltextzugriff (PDF)

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

The Journal of molecular diagnostics : JMD, 2014-05, Vol.16 (3), p.343-349

2014

Volltextzugriff (PDF)

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase

Molecular cancer therapeutics, 2004-10, Vol.3 (10), p.1215

2004

Volltextzugriff (PDF)

Lomeguatrib, a Potent Inhibitor of O 6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-03, Vol.12 (5), p.1577-1584

2006

Volltextzugriff (PDF)

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

Clinical pharmacokinetics, 2005-01, Vol.44 (10), p.1067-1081

2005

Volltextzugriff (PDF)

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

JNCI : Journal of the National Cancer Institute, 2002-10, Vol.94 (19), p.1484-1493

2002

Volltextzugriff (PDF)

Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2524-2524

2016

Volltextzugriff (PDF)

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2513-2513

2016

Volltextzugriff (PDF)

Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2599-2599

2014

Volltextzugriff (PDF)

Interstitial lung disease in lung cancer. Separating disease progression from treatment effects

Drug safety, 2005-01, Vol.28 (2), p.103-113

2005

Volltextzugriff (PDF)

Apoptosis pathway-targeted drugs—from the bench to the clinic

Biochimica et biophysica acta, 2004-12, Vol.1705 (1), p.53-66

2004

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(70)
Dissertationen
(1)

Sprache

Englisch
(68)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(35)
Humans
(30)
Oncology
(22)
Antineoplastic Agents - Therapeutic Use
(13)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Female
(10)
Animals
(8)
Antineoplastic Agents - Pharmacology
(8)
Pharmacology & Pharmacy
(8)
Pharmacology. Drug Treatments
(8)
Non-Small Cell Lung Cancer
(7)
Male
(6)
Antineoplastic Agents
(5)
Antineoplastic Agents - Pharmacokinetics
(5)
Apoptosis
(5)
Cell Line, Tumor
(5)
Chemotherapy
(5)
Gefitinib
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Temperature-Dependent Infrared Refractive Index of Polymers from a Calibrated Attenuated Total Reflection Infrared Measurement

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

ZD1839 (Iressa™): For More Than Just Non‐Small Cell Lung Cancer

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

Multiplexed Assays for Detection of Mutations in PIK3CA

Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer

Perspectives on Anti-HER Monoclonal Antibodies

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone

Dual repair modulation reverses Temozolomide resistance in vitro

Biomarkers of cell death applicable to early clinical trials

EGFR T790M mutation testing within the osimertinib AURA Phase I study

Panitumumab: A Viewpoint by Malcolm Ranson

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase

Lomeguatrib, a Potent Inhibitor of O 6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)

Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation

Interstitial lung disease in lung cancer. Separating disease progression from treatment effects

Apoptosis pathway-targeted drugs—from the bench to the clinic

Aktive Filter

Suchergebnisse filtern